Amycretin, now named zenagamtide, cuts A1C and weight in phase 2 diabetes trial

Novo Nordisk presented phase 2 results at the American Diabetes Association meeting for zenagamtide, the new name for amycretin, a single-molecule GLP-1 and amylin receptor agonist. In 262 adults with type 2 diabetes given weekly injections for 36 weeks, A1C fell by up to 1.71 percentage points from a baseline of 7.8%, and body weight fell by up to 14.6% on 40 mg versus 2.1% on placebo. An oral form is being studied separately.